Edoxaban

CHEMBL1269025 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

10-14 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

548.1 g/mol

LogP

1.4

Phase

4

A direct oral anticoagulant that inhibits factor Xa, a key protein in the blood clotting cascade, used to prevent stroke in patients with atrial fibrillation and to treat blood clots in veins. It does not require routine blood monitoring unlike older blood thinners.

น้ำหนักโมเลกุล

548.0530 g/mol

LogP

1.40

TPSA

165.00 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Hypertension Breast Cancer Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

หมวดหมู่ยา

B — B - Blood and Blood Forming Organs

กลไกการออกฤทธิ์

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Pharmacokinetics (PK)

Half-Life 10-14 hours

Pharmacodynamics (PD)

กลไก

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1

InChI

InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1

Molecular Formula

C24H30ClN7O4S

HBD / HBA

3 / 8

พันธะที่หมุนได้

5

อะตอมหนัก

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A direct oral anticoagulant that inhibits factor Xa, a key protein in the blood clotting cascade, used to prevent stroke in patients with atrial fibrillation and to treat blood clots in veins. It does not require routine blood monitoring unlike older blood thinners.

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Key pharmacokinetic parameters for Edoxaban: Half-life: 10-14 hours.

Yes, Edoxaban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

Same Drug Class

Warfarin Small molecule Clopidogrel Small molecule Apixaban Small molecule Rivaroxaban Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1269025. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 10280735. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Edoxaban บน PillFYI

โครงสร้าง

ข้อมูลด่วน

Class: B - Blood and Blood Forming Organs
สูตร: C24H30ClN7O4S
คำพ้องความหมาย: 1

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Edoxaban

ด้านการรักษา

หมวดหมู่ยา

กลไกการออกฤทธิ์

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

คำถามที่พบบ่อย

Related Drugs

Same Drug Class

References & Data Sources

Embed This Widget